New market study, "Zimbabwe Pharmaceuticals & Healthcare Report Q3 2016", has been published

Zimbabwe's ongoing economic crisis is continuing to take a toll on the country's pharmaceutical and healthcare sector. Severely underfund ed public healthcare services and high poverty levels have made access to formal treatments difficult, with many turning to traditional healers instead. Despite government pledges to improve healthcare access in recent years, we have yet to see any substantial developments, with the country still heavily reliant on international aid for essential medicines. Further issues including a high abundance of counterfeit drugs and political instability make Zimbabwe one of the least attractive markets in the regi on for multinational drugmakers.

Headline Expenditure Projections

Pharmaceuticals: USD380mn in 2015 to USD400mn in 2016; +4.7% in US dollar terms. Forecast unchanged from last quarter .

Risk/Reward Index

In BMI's Risk/Reward Index (RRI) for Q316, Zimbabwe scores a poor 25.0 out of 100, unchanged from last quarter. The country is the second least attractive out of the 31 markets surveyed in the Middle East and Africa region, after Angola. Despite its rapidly growing population, Zimbabwe will remain one of the least-attractive pharmaceutical and healthcare markets regionally and globally, due to the elevated political, economic and social risks, as well as the lack of finances for adequate healthcare provision and capacity utilisation.

Full Report Details at
- http://www.fastmr.com/prod/1197583_zimbabwe_pharmaceuticals.aspx?afid=301

Latest Updates

In May 2016, preliminary result from the Zimbabwe Demographic Health Survey (ZDHS) revealed that in 2015, maternal mortality had declined to 651 deaths per 100,000 deliveries from 960 in the 2010/11 survey, translating to an average of seven deaths per day.

Over the same period, the ZDHS also found that the number of children who were vaccinated in line with the recommended child health practice has improved with an average of 73% coverage throughout the country, although one in 15 children born in the past five years died before the age of five.

According to local press reports in May 2016, the Zimbabwean Treasury allocated a meagre USD3.5mn for the procurement of medicines in government healthcare institutions for 2016.

In May 2016, the John E. Fogarty International Centre at the National Institutes of Health awarded a five-year grant of USD1.3mn to the University of Buffalo and the University of Zimbabwe for a HIV Research Training Program.

Physicians at Zimbabwean public hospitals have warned that more people are turning to traditional medicine and healers as the country's continuing economic crisis is making formal healthcare access increasingly difficult.

BMI Economic View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Qatar Pharmaceuticals & Healthcare Report Q3 2016
- Turkey Pharmaceuticals & Healthcare Report Q3 2016
- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- United Arab Emirates Pharmaceuticals & Healthcare Report Q3 2016